IDEAYA Biosciences, Inc. Common Stock (IDYA)
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company leverages insights from tumor genetics and tumor immune profiling to create precision medicines aimed at improving outcomes for patients with various cancers. Founded in 2015, IDEAYA is based in South San Francisco, California, and emphasizes innovative approaches in oncology treatments.
Company News
IDEAYA Biosciences reported a Q2 2025 net loss of $0.88 per share with no revenue, but maintained strong cash reserves of $991.9 million. The company continues advancing its cancer therapy pipeline, with key clinical trials progressing in darovasertib and other oncology programs.
The melanoma market is expected to surge between 2025-2034 due to increasing incidence, emerging therapies, heightened UV exposure, and diagnostic advancements. Several new therapies are in development, with potential to transform treatment options for melanoma patients.
Kura Sushi USA reported weak Q3 results, missing analyst estimates. Several other companies, including LegalZoom.com, Stardust Power, 10x Genomics, IDEAYA Biosciences, and uniQure, also saw their shares decline in pre-market trading.
Morphic Holding surged 75.1% on news of Eli Lilly's $3.2 billion acquisition. Ideaya Biosciences gained 15.3% after positive phase 2 trial results. Etsy fell 5.3% due to product sale restrictions. Intel jumped 6.2% following positive remarks from Melius Research.
BTIG increased its price target on Ideaya Biosciences to $62 from $55, citing positive data from a Phase 2 study of the company's drug IDE397 as a monotherapy for treating certain cancers.